Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 52

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 52
---
 us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition,
companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if we are able to obtain a license
under such intellectual property rights, any such license may be non-exclusive, which may allow our competitors access to the same technologies
licensed to us.

Moreover, some of our owned and in-licensed patents
or patent applications or future patents may be co-owned with third parties. If we are unable to obtain an exclusive license to any such
third-party co-owners’ interest in such patents or patent applications, such co-owners may be able to license their rights to other
third parties, including our competitors, and our competitors could market competing diagnostic tests or therapeutic products and technology.
In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties,
and such cooperation may not be provided to us. Furthermore, our owned and in-licensed patents may be subject to a reservation of rights
by one or more third parties. Any of the foregoing could have a material adverse effect on our competitive position, business, financial
conditions, results of operations, and prospects.

| 23 |

Our competitive position depends on protection of our intellectual property.

Development and protection of our intellectual property
are critical to our business. If we do not adequately protect our intellectual property, or if competitors develop technologies incorporating
the same or similar technologies that already are in the public domain, those competitors may be able to develop similar technologies
to our own. Our success depends in part on our ability to obtain patent protection for our diagnostic tests, therapeutic products, or
processes in the U.S. and other countries, protect trade secrets, and prevent others from infringing on our proprietary rights.

Since patent applications in the U.S. are maintained
in secrecy for at least portions of their pendency periods (published on U.S. patent issuance or, if earlier, 18 months from earliest
filing date for most applications) and since other publication of discoveries in the scientific or patent literature often lags behind
actual discoveries, we cannot be certain that we are or will be the first to make the inventions to be covered by our patent applications.
The patent position of biopharmaceutical and biotechnology firms generally is highly uncertain and involves complex legal and factual
questions. The U.S. Patent and Trademark Office has not established a consistent policy regarding the